Menopur (Menotrophin)

Menotrophin contains both FSH and LH activity. After subcutaneous injection it binds to FSH and LH receptors on ovarian cells, stimulating follicle growth, estrogen production and final maturation of the dominant follicle, which leads to ovulation.

The dose of Menopur is individualized. The prescribing clinician determines the amount and schedule based on the patient’s ovarian response, treatment protocol and monitoring results. No fixed regimen can be provided without a medical prescription.

Menopur is intended for use before conception to achieve pregnancy. Its safety in an established pregnancy or while breastfeeding has not been established, and it should only be used under specialist supervision in the context of fertility treatment.

To order Menopur, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and necessary import documentation.

Menopur provides combined FSH and LH activity in a single preparation, which can simplify dosing compared with separate FSH‑only products. Clinicians may choose it for patients who benefit from LH supplementation, while other gonadotropins may be preferred when only FSH activity is required.

Menopur must be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Before use, allow the vial to reach room temperature if required, and handle with aseptic technique to maintain sterility.

Menopur is given as a subcutaneous injection, typically into the abdomen or thigh. The injection is performed by a trained healthcare professional or a patient who has been instructed in proper aseptic technique and dosing.

The most serious risks include ovarian hyperstimulation syndrome, which can be severe and require hospitalization, multiple pregnancy, and rare severe allergic reactions. Patients are monitored closely with ultrasound and hormone measurements to detect these complications early.

Menopur should not be used in individuals with known hypersensitivity to menotropin, active ovarian cysts, uncontrolled thyroid disease, or those who are pregnant. It is also contraindicated in patients with certain hormone‑dependent cancers or severe uncontrolled medical conditions.